Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Siri M Ippagunta und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Ependymoma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, RCD Foundation Scientific Fellowship, NBTS.
Abstract (Originalsprache)
Background
Ependymoma (EPN) is the third most common pediatric brain tumor with no targeted therapies available to patients. In supratentorial ependymoma, the most frequent driver alteration is a gene fusion between ZFTA and RELA (denoted ZR), which leads to constitutive localization of ZR in the nucleus. Because ZR is not currently druggable, we tested whether ZR expression leads to aberrant protein interactions that could represent therapeutic vulnerabilities.
Methods
Using CRISPR-Cas9 pooled screening, we identified many novel druggable ZR-interacting proteins including XPO1, CARM1, SMARCA4, and CDK1. We focused on the nuclear export protein (XPO1), given the ability of most XPO1 inhibitors (ie, selinexor) to cross the blood-brain barrier, FDA approval, and have documented safety profiles in children.
Results
We found that specific nuclear ZR levels are needed for cell proliferation and are regulated by XPO1. Increased ZR accumulation in the nucleus does not increase oncogenic gene expression but drives tumor cells out of the cell cycle, as compared to a defective ZR DNA-binding mutant. Treatment of ZR-driven patient-derived mouse models with selinexor impairs cell growth and extends survival of animals in vivo. The combination of selinexor treatment with gemcitabine and ribociclib (used in a clinical trial for relapsed EPN at St. Jude Children’s Research Hospital [SJDAWN]) further extends mouse survival.
Conclusion
Our findings demonstrate that ZR-interacting proteins constitute therapeutic leads and that XPO1 is critical for titrating “goldilocks” levels of ZR nuclear expression. We identify a novel combination therapy of selinexor, gemcitabine, and ribociclib that may be immediately translated into clinical trials for EPN patients that are currently without targeted treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Neurobiology and Brain Tumor Program, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Center of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Chemical Engineering, Rice University, Houston, Texas, USA.
- Cancer and Cell Biology Program, Baylor College of Medicine, Houston, Texas, USA.
- Center for In Vivo Imaging and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Siri M Ippagunta, Amir Arabzade, Srinidhi Varadharajan, Erik Emanus, Amanda Bland, Alisha Kardian, Nicholas Laboe, Hua Sun, Tuyu Zheng, Mark Zhai, Wilda Orisme, Melissa Johnson, Gregory H Turner, Jeffrey Steinberg, Martine F Roussel, Anang Shelat, Thomas E Merchant, Benjamin Deneen, Michael D Taylor, Sameer Agnihotri, Shondra Pruett-Miller, Jacob A Steele, Anoop Murthy Kavirayani, David W Ellison, Arzu Onar-Thomas, Giles W Robinson, Stephen C Mack
Förderung
- NCI NIH HHS
- RCD Foundation Scientific Fellowship
- NBTS
- St. Baldrick's Foundation Career Development
- Matthew Larson Brain Tumor Research
- V Scholar Translational Grant
- St. Jude Children's Research Hospital Research Collaborative on Transcription Regulation in Pediatric Cancer
- Alex's Lemonade Stand Foundation "A" Award
Zitieren
APA
Ippagunta, S. M., Arabzade, A., Varadharajan, S., Emanus, E., Bland, A., Kardian, A., Laboe, N., Sun, H., Zheng, T., Hancock, A., Zhai, M., Caesar, E., Park, M., Orisme, W., Johnson, M., Rodgers, B., Turner, G. H., Steinberg, J., Freeman, B., …, & Bertrand, K. C. (2026). Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag100
Vancouver
Ippagunta SM, Arabzade A, Varadharajan S, Emanus E, Bland A, Kardian A, et al. Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag100
BibTeX
@article{Ippagunta2026,
author = {Ippagunta, Siri M and Arabzade, Amir and Varadharajan, Srinidhi and Emanus, Erik and Bland, Amanda and Kardian, Alisha and Laboe, Nicholas and Sun, Hua and Zheng, Tuyu and Hancock, Amelia and Zhai, Mark and Caesar, Emma and Park, Maxwell and Orisme, Wilda and Johnson, Melissa and Rodgers, Brittany and Turner, Gregory H and Steinberg, Jeffrey and Freeman, Burgess and Roussel, Martine F and Shelat, Anang and Kriwacki, Richard W and Merchant, Thomas E and Deneen, Benjamin and Taylor, Michael D and Agnihotri, Sameer and Pruett-Miller, Shondra and Steele, Jacob A and Kavirayani, Anoop Murthy and Ellison, David W and Onar-Thomas, Arzu and Robinson, Giles W and Mack, Stephen C and Bertrand, Kelsey C},
title = {Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag100}
}
EUVIMED